Table 5 Optimal serum 25(OH)D threshold values for minimizing the risk of adverse outcomes in diverse populations as previously reported
Population | Threshold value (nmol/L) | Outcomes |
|---|---|---|
Osteoarthritis [44] | 27.7 | Cardiovascular mortality |
54.4 | All-cause mortality | |
Hyperlipidemia [13] | 63 | Cardiovascular mortality |
64 | All-cause mortality | |
Type 2 Diabetes | 50 | Dementia [45] |
50 | Cardiovascular disease [46] | |
Adolescents [47] | 58.1 | Refractive status |
Coronary Heart Disease [48] | 50 | Recurrent Cardiovascular Events |
Metabolic dysfunction associated fatty liver disease [40] | 50 | All-cause mortality |
Australian community [49] | 55 | Cardiovascular mortality |
65 | All-cause mortality | |
Dutch population [50] | 46—68 | Multiple outcomes (mortality, hypertension, cardiovascular disease, etc.) |
COVID-19 [51] | 41.19 | Infection and Severity |
Cancer survivors (the present study) | 87.9 | All-cause mortality |
88.7 | Cardiovascular mortality | |
84.6 | Cancer-specific mortality |